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During the information event, attending female parents and guardians were interviewed and completed questionnaires (Appendix 1, available in the online version of this article), after which they attended a session at which information on cervical cancer, the vaccine for primary prevention and screening for the disease was provided by a medical doctor in the form of a 15-minute PowerPoint presentation as well as through the distribution of information leaflets in English or Tswana. During the vaccination programme, telephonic interviews were conducted, repeating the questions that tested knowledge and screening behaviour (Appendix 1, available in the online version of this article).
Female parents and guardians attending the information events were invited to take part in self-administered HPV screening and to take a screen kit for themselves as well as for a friend or family member. The screen kit consisted of a tampon with user instructions; women were to insert the tampon vaginally and remove it after one hour. The used tampon was placed in a container with buffer and, together with personal information, returned to the school in a sealed envelope. DNA was extracted from the tampon specimens and tested using Roche linear array for HPV DNA testing as described previously. [6] Parents and guardians of girls aged 9 years and older in grades 4 -7 were invited to provide consent, and all girls were requested to provide consent for HPV vaccination. The vaccine was administered per protocol by a team of registered nurses during school hours. Both bivalent and quadrivalent vaccines donated by the manufacturing companies were available to be administered.
The ages and previous screening histories of women who accepted the invitation to screen were determined to assess whether an appropriate target population for secondary prevention was reached. HPV test results were interpreted as positive if DNA of any of the 15 high-risk viral types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) were demonstrated, and as invalid if no DNA amplification occurred as tested by the internal control. Women testing positive for the two most oncogenic HPV types (16 and 18) were reported separately.
Definitions
The invited cohort (IC) was defined as all female learners enrolled in the selected schools in grades 4 -7. The consented cohort (CC) was defined as participants with written consent and assent from the learner. Girls with consent whose parents or guardians did not attend vaccine events were included in the CC. The vaccinated cohort (VC) was defined as all girls who received one vaccine dose. Vaccine uptake rates were calculated in a number of ways in order to allow comparison with other published HPV vaccine reports. The consented uptake rate (CUR) was calculated as VC/CC, with the invited uptake rate (IUR) calculated as VC/IC.
Vaccine completion was calculated using the vaccinated cohort as denominator. The vaccine completion rate (VCR) was calculated using all girls who received all three vaccine doses. Girls who received only two vaccine doses within a short period of time were then separated from those who received the two vaccines at least 6 months apart, and the latter group was considered sufficiently vaccinated based on recent data suggesting protective antibody levels against vaccine HPV B1  61  54  54  0  1  0  0  53  53   B2  87  79  79  2  3  0  1  74  75   B3  183  118  119  1  1  3  6  108  114   B4  223  127  127  0  3  4  3  117  120   B6  123  59  59  1  1  3  7  47  54   B7  166  70  70  1  5  1  2  61  63   B8  181  136  136  0  1  4  0  131  131   B9  155  99  95  3  0  3  40  48  88   Subtotal  1 179  742  739  8  15  18  59  639 types in similar recipients. [7, 8] The insufficiently vaccinated rate (IVR) was calculated using the number of girls who received only one dose, or two doses <6 months apart.
Statistical analysis
Questionnaire data were obtained from women who participated in the study and consisted of basic demographic data as well as data on access to and use of healthcare facilities. In addition, knowledge about cervical cancer and prevention of the disease was tested before and after the information event. Knowledge scores were calculated by awarding points for correct answers to a maximum score of 5 marks each for symptoms of, screening for and vaccination against cervical cancer. Changes in knowledge as tested by the same questions asked before and after the information event were measured and compared between groups. A p-value of <0.05 was regarded as statistically significant.
Women who participated in self-screening were compared with a matched control group of women who did not participate. Within the participants of self-screening, data from all women with positive screen results were compared with a matched subgroup of those who screened negative. Matching of both control groups was done using age and the school attended by the child. There were no significant differences with regard to level of education, employment status and access to healthcare between the three groups of women. 
Results

Vaccination data
In the ten schools included in the project, the IC consisted of 1 654 girls, of whom 1 059 had given full consent (CC); 1 053 girls received the first vaccine dose (VC). The CUR was 99.4% and the IUR 64.0%. In the CC group, 498 parents or guardians provided informed parental consent during the information events held at the different schools, while 561 provided written informed consent on the basis of the information leaflet that learners took home. Five hundred and sixty-nine parents or guardians attended the information events and questionnaire interviews, while 1 085 received only leaflet information. Consent for vaccination was therefore provided by 561 of 1 085 parents (51.7%) who received only leaflet information, and by 498 of 569 (87.5%) who attended the information events (p<0.0001).
In eight of the ten schools, all three doses of the vaccination were completed in the same calendar year. Vaccine completion rates were superior in these schools compared with the two schools in which vaccination was scheduled over two calendar years. Vaccine uptake and VCRs per school as well as the effect of scheduling over one and two calendar years are shown in Table 1 . No serious adverse events related to vaccination were reported.
Screening results
The 569 female parents or guardians attending the information events at the different schools were invited to take selfscreening kits home. A total of 795 screen tests were handed out, of which 253 (44.5%) were returned and tested for the presence of high-risk HPV (hrHPV) DNA. The mean age (standard deviation) of the screened population ( Fig. 1 ) was 38.3 (10.2) years (95% confidence interval 37.0 -39.6), and the median age was 38.5 years.
Of the 253 samples tested, 9 (3.6%) were reported as invalid, 169 (66.7%) tested negative for hrHPV and 75 (29.6%) were positive for any hrHPV. The hrHPV results are shown in Fig. 2 . Twenty-three samples (9.1%) were positive for HPV type 16 and/or 18, and 52 (20.5%) were positive for one or more of the remaining 13 high-risk types. Of the 75 positive specimens, 43 (57.3%) had a single type and 32 (42.7%) tested positive for more than one hrHPV.
Cervical cancer knowledge
Knowledge scores for cervical cancer symptoms, screening and vaccines for the total group before and after the educational intervention are shown in Fig. 3 . Initial knowledge of all aspects was insufficient, but improved scores were obtained in the second questionnaire.
Considering the screened and unscreened groups, there was no difference in initial knowledge of cervical cancer and its symptoms, which was poor in both groups. Around 70% in both groups obtained 0 or 1 out of the potential 5 marks awarded. Among women who participated in self-screening, the level of cervical cancer knowledge improved significantly after the information event (n=132; p<0.001) ( Table 2) , while among unscreened women the improvement was not statistically significant (n=41; p=0.06) ( Table 2) . With regard to knowledge of cervical cancer prevention, knowledge of screening and vaccination improved significantly after the information event among screened and unscreened groups (data not shown, p<0.001).
Screening behaviour
Self-reported previous screening behaviour did not differ significantly between women who participated in self-screening compared with those who did not (p=0.169); 51.2% of women who participated in self-screening reported no previous screening ever or did not know whether they had had screening in the past, compared with 48.8% of non-participants.
It is interesting that after participating in the project, 45 of 131 screened women (34.3%) reported that their last 'cervical cancer test' was more than 5 years ago. Despite this disparity, there was still a significant improvement in reported screening behaviour in this group between the two questionnaires (p<0.001) ( Table 3 ) compared with the control group, which did not show significant improvement (p=0.036) ( Table 3 ).
Discussion
Vaccine uptake data differ worldwide and are influenced by numerous social, religious and economic factors. In addition, vaccine programme and communication strategies have a very large effect on uptake. Uptake of HPV vaccines is low in the USA and Germany [9, 10] and high in Australia, [11] while uptake rates in Africa vary. [12] [13] [14] Vaccine uptake, calculated as the proportion of girls who received one vaccine dose from the total IC, was 64.0% for the total group in this study. The project protocol allowed for the provision of only sketchy information to prospective participants, because another aim of the study was to test baseline knowledge. Although it can be argued that interested and informed parents were more likely to attend, the relatively low vaccine uptake (51.7%) among parents who did not attend the information event compared with those who did attend (87.5%) could probably be attributed in part to this lack of information.
Moodley et al. [15] reported overall HPV vaccine uptake in an implementation study in KwaZulu-Natal Province, SA, of 99.7%, 97.9% and 97.8% for the first, second and third vaccination doses, respectively. These data represent the uptake and completion rates of those who consented, but uptake as a proportion of girls available for vaccination was not provided. In the current study, similar success in vaccination of consented girls of 99.4%, 98.6% and 82.6% for one, two and all three doses, respectively, was achieved. In addition to uptake and completion rates, the proportion of the VC that received at least two vaccine doses at least 6 months apart was calculated. To our knowledge it is the first time that HPV vaccine data from an implementation or demonstration project have been presented in this way, and these results therefore cannot be compared.
In a school-based programme, it is acknowledged that VCRs are largely influenced by the number of follow-up visits to Vaccination in a single calendar year was more successful than vaccination scheduled over two years, as reflected by better VCRs (86.5% v. 73.5%) and SVRs (94.5% v. 77.4%). The difference can possibly be attributed to the December holiday break, children changing schools and promotion to secondary schools, which resulted in fewer girls receiving the important third dose. Although not surprising, this is to our knowledge the first confirmation of this effect reported from SA. The projected large loss of immune response and resulting herd immunity caused by an inefficiently vaccinated population is of huge importance for the planning of all vaccine rollout programmes using school-based infrastructure.
Screening uptake, calculated as the proportion of women screened from those invited, was 44.5% in this study. Furthermore, in this study 253 women took up screening, of whom more than half reported no previous cervical cancer screening. Molecular screening results identified cervical cancer risk in 28.8% and a high risk for future disease in 9.1%. Using the school infrastructure as well as mobile phone technology, all women received screen results and this was confirmed for all screen-positive women.
All five of these parameters compare favourably to the limited data available for the existing cytology-based countrywide screening programme. According to the World Health Organization, cervical cytology coverage of eligible women in SA for the period 2000 -2006 was estimated to be 17%. [16] Screening will have the largest effect on cancer incidence if coverage is large, the correct high-risk target group is reached, and the biggest possible number of screen-positive women can get results and receive preventive therapy. HPV screening in low-resource settings is feasible, and self-sampling offers the added benefits of eliminating a clinic visit, speculum examination and the need for a healthcare provider to perform screening.
In addition to screening, education about cervical cancer symptoms and screening was successfully linked to the cervical cancer vaccine by the provision of information to parents or guardians of girls invited to be vaccinated. Knowledge about cervical cancer-related matters was lacking in this group of urban mothers, but improved following the provision of information. Neither demographics nor baseline knowledge predicted screening uptake in this study. Positive screening behaviour was associated with an improvement in knowledge about cervical cancer. As expected, most screening participants reported an improvement in screening behaviour after the tampon test, reflecting an understanding of the intention of the test. The finding that some women who took part in self-screening were not aware of the fact that they were screened could be attributed to a lack of knowledge or the structure of the questionnaire.
Conclusion
Implementation of HPV vaccination in a primary school-based programme was hugely successful. No serious adverse events were reported, and uptake rates of 64.0% of the IC and 99.4% of the CC were achieved. Vaccine completion was optimal when all vaccine doses were offered within a single calendar year.
Self-screening tests reached the ideal target group, and results were successfully reported to all participants. Linking cervical cancer screening to the cervical cancer vaccine was possible by providing women the opportunity to self-sample. This is a novel approach that would require some adaptive strategies, but was feasible and practical in the setting of this trial.
Knowledge about cervical cancer, its symptoms and prevention is generally poor, and school-based vaccine programmes offer a unique opportunity to provide appropriate information. This report of the Gauteng part of the VACCS project confirmed a measurable improvement in knowledge following health education. In addition, it was demonstrated that improved knowledge correlated with the uptake of screening.
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